content top

Bevacizumab for Subfoveal Choroidal Neovascularization in a Child

Posted by , and on Oct 10, 2013 in Bevacizumab Avastin, Neovascularization / angiogenesis, Pediatry

Poster Gavin Tan Introduction: Choroidal neovascularization (CNV) is rare but important cause of visual impairment in children. It is often idiopathic or secondary to inflammation, optic nerve head abnormalities or retinal dystrophies. There is a lack of clinical trials assessing the treatment of CNV in children. Methods: A 11-year-old boy with no past medical or ocular history presented with 3 months duration of reduced vision in his...

Read More

Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Subretinal Fluid in Diabetic Retinopathy

Posted by , , , and on Oct 10, 2013 in Bevacizumab Avastin, Diabetes mellitus, Triamcinolone Acetonide and Steroids

Poster V. Levent Karabas Purpose: To evaluate the efficacy of intravitreal triamcinolone acetonite (IVT) injection versus intravitreal bevacizumab (IVB) injection in the management of subretinal fluid in patients with diabetic retinopathy. Methods: Forty-seven patient affected by diabetic macular edema with subretinal fluid were included. Patients were assigned randomly to two groups. IVT group, patients who received 4mg/0.1ml...

Read More

Retinal Vessel Response to Intravitreal Bevacizumab in Diabetic Eyes

Posted by , and on Oct 7, 2013 in Bevacizumab Avastin, Retinal vessels

Poster 2 Osman Cekic To measure retinal vessel diameters following intravitreal bevacizumab injection in eyes with diabetic macular oedema.

Read More

Morphological Changes in Spectral Domain Optical Coherence Tomography Guided Bevacizumab Injections in Wet AMD, 12-months Results

Posted by , and on Oct 4, 2013 in Bevacizumab Avastin, Exsudative ARMD, OCTs

http://www.dailymotion.com/video/x169htw Advantage: This paper aims to describe retinal changes during Spectral Domain Optical Coherence Tomography (SD-OCT) guided Bevacizumab treatment for neovascular age- related macular degeneration (AMD). Material and Methods: 47 eyes of 45 patients with wet AMD treated on demand with Bevacizumab. We used 3-dimensional SD-OCT to measure photoreceptor defects and subretinal fibrosis. The main efficacy...

Read More

The Appropriate Timing of Pars Plana Vitrectomy After Pretreatment with Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Posted by , and on Oct 4, 2013 in Bevacizumab Avastin, Proliferative diabetic retinopathy, Vitrectomy

http://www.dailymotion.com/video/x16b54h Purpose: The purpose of this study was to determine the appropriate timing of pars plana vitrectomy after pretreatment with intravitreal bevacizumab (IVB) for proliferative diabetic retinopathy using histopathological examination of epiretinal membrane biopsies. Material & Methods: This prospective study was conducted in Maghrabi Eye Hospital & Kuwait University Hospital, Sana, between...

Read More

Efficacy and Safety of Intravitreal Bevacizumab Monotherapy for Threshold Retinopathy of Prematurity

Posted by , , , , , , , , , , , and on Oct 4, 2013 in Bevacizumab Avastin, Retinopathy of prematurity

http://www.dailymotion.com/video/x168ukp The introduction of Intraocular Anti-VEGFs agents have significantly improved the management of a wide variety of neovscular ocular diseases including retinopathy of prematurity (ROP). In our hands, monotherapy treatment with intravitreal bevacizumab (IVB) is a favourable treatment modality in management of threshold ROP. In eyes with iris rubeosis, rigid pupils and vitreous haze where it is...

Read More
content top